Comparing TACE-Lenvatinib with TACE-Lenvatinib-ablation for recurrent liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of combining transarterial chemoembolization (TACE) with Lenvatinib and ablation techniques for patients with intermediate recurrent hepatocellular carcinoma (RHCC). It aims to determine if the addition of ablation improves patient outcomes compared to TACE and Lenvatinib alone. The study will involve patients diagnosed with intermediate-stage RHCC, focusing on those who have not shown tumor progression after initial TACE treatment. By identifying the most responsive patients, the study seeks to enhance treatment strategies for this heterogeneous condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. 18-75 years;
2. RHCC diagnosed by imaging;
3. intermediate-stage RHCC (two to three lesions which at least one was \>3 cm in size or more than three tumors);
4. the tumor number was no more than six, and the maximum tumor diameter was ≤5 cm;
5. absence of extrahepatic metastasis or macrovascular invasion;
6. Child-Pugh class A or B;
7. TACE as initial treatment after tumor recurrence and showed no tumor progression after TACE.
8. life expectance \>3 months;

Exclusion Criteria:

1. under 18 years or over 75 years of age;
2. primary intermediate-stage HCC;
3. RHCC with more than six tumors, or single RHCC

(5) RHCC \>5cm; (6) extrahepatic metastasis; (7) macrovascular tumor thrombus;

Where it's running

• Chinese PLA General hospital
  Beijing, None Selected, China Recruiting

Study contacts

• Study coordinator: Qunfang Zhou
• Email: zhouqun988509@163.com
• Phone: 86 19868000115

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Treatment for ruptured liver cancer using TACE, Lenvatinib, and PD-1 inhibitors

  This study is testing a new treatment that combines a special type of chemotherapy with Lenvatinib and PD-1 inhibitors to see if it can help patients with serious liver cancer that has ruptured.

  Recruiting Sun Yat-sen University · Beijing, None Selected · NCT06740370

• Combining TIPS with Lenvatinib and PD-1 inhibitors for advanced liver cancer with portal vein tumor thrombus

  This study is testing if combining a special procedure with two cancer treatments can help people with advanced liver cancer and a serious blood clot in the portal vein feel better and have better results.

  Recruiting Sun Yat-sen University · Beijing, None Selected · NCT06622031

• Ablation combined with lenvatinib and PD-1 inhibitor for advanced liver cancer with limited metastases

  This study is testing if combining a targeted treatment with a special type of therapy can help people with advanced liver cancer that has spread a little, to see if it improves their chances of living longer.

  Recruiting Sun Yat-sen University · Beijing, None Selected · NCT06550921

• Combining chemotherapy and targeted therapy for advanced liver cancer

  This study is testing whether combining a specific type of chemotherapy with two targeted therapies can help people with advanced liver cancer feel better and improve their treatment results.

  Recruiting Sun Yat-sen University · Beijing, Beijing Municipality · NCT06333561

• Combining Lenvatinib, Tislelizumab, and TACE for Liver Cancer Treatment

  This study is testing a new combination treatment for liver cancer to see if it can help patients at high risk of their cancer coming back after surgery.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT05920863

• Neoadjuvant treatment for resectable recurrent liver cancer

  This study is testing if a new combination of immune therapy and medication can help people with resectable recurrent liver cancer have better outcomes after surgery.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT04615143

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.